.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Farmers Insurance
Citi
UBS
Colorcon
Queensland Health
Chubb
Mallinckrodt
Novartis

Generated: July 24, 2017

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?

MYLAN PHARMS INC has two hundred and thirty-eight approved drugs.

There are twelve US patents protecting MYLAN PHARMS INC drugs. There are twenty-nine tentative approvals on MYLAN PHARMS INC drugs.

There are two hundred and nineteen patent family members on MYLAN PHARMS INC drugs in forty countries.

Summary for Applicant: Mylan Pharms Inc

Patents:12
Tradenames:195
Ingredients:185
NDAs:238
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL206721-005Nov 10, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
FROVATRIPTAN SUCCINATE
frovatriptan succinate
TABLET;ORAL202931-001Aug 28, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
LITHIUM CARBONATE
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL202288-001Jun 29, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
RISPERIDONE
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL091537-004Mar 30, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
PINDOLOL
pindolol
TABLET;ORAL074013-001Sep 24, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc
DENAVIR
penciclovir
CREAM;TOPICAL020629-001Sep 24, 1996► Subscribe► Subscribe
Mylan Pharms Inc
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999► Subscribe► Subscribe
Mylan Pharms Inc
LUXIQ
betamethasone valerate
AEROSOL, FOAM;TOPICAL020934-001Feb 28, 1999► Subscribe► Subscribe
Mylan Pharms Inc
DENAVIR
penciclovir
CREAM;TOPICAL020629-001Sep 24, 1996► Subscribe► Subscribe
Mylan Pharms Inc
MAXZIDE
hydrochlorothiazide; triamterene
TABLET;ORAL019129-001Oct 22, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MYLAN PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
ketoconazole
Foam2%
EXTINA
7/30/2009
betamethasone valerate
Foam0.12%
LUXIQ
8/10/2007
clobetasol propionate
Topical Foam0.05%
OLUX
6/27/2005

Non-Orange Book Patents for Mylan Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,187,922 Process for the preparation of purine derivatives► Subscribe
8,586,066Topical antifungal composition► Subscribe
8,629,128Vitamin formulation► Subscribe
9,486,394Pharmaceutical foam► Subscribe
5,075,445 Guanine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mylan Pharms Inc Drugs

Country Document Number Estimated Expiration
South Korea930006349► Subscribe
Canada2214436► Subscribe
Denmark8504246► Subscribe
Australia2004206769► Subscribe
Israel214118► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mylan Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/1999Austria► SubscribePRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/98/089/001-010 19981211; FIRST REGISTRATION: BE K (1998) 4288-DE 19981211
00032Netherlands► SubscribePRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
70035Netherlands► SubscribePRODUCT NAME: NARATRIPTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER NARATRIPTAN-HYDROCHLOR IDE; NAT. REGISTRATION NO/DATE: RVG 21444 19970801; FIRST REGISTRATION: SE 13382 19970310
C/GB05/030United Kingdom► SubscribePRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Citi
Boehringer Ingelheim
Express Scripts
Cantor Fitzgerald
Medtronic
Harvard Business School
Dow
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot